% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • fansteman fansteman Oct 25, 2012 4:48 AM Flag

    phase I ICT-107 up-date presented at SITC

    Posted yesterday on the the virtual-strategy website: "At the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting today, John S. Yu, MD and colleagues from Immunocellular Therapeutics Ltd. presented results of a phase I study of 21 patients. The study evaluated the safety and immune responses to a cellular dendritic cell vaccine, ICT-107, made from the patient’s white blood cells and armed with peptides that target six different tumor specific proteins found on glioblastoma tumor and cancer stem cells.

    Patients received standard of care - surgery and chemo-radiation - followed by three vaccinations of ICT-107 every two weeks. Results showed that of the newly diagnosed patients, the median overall survival (OS) was 38.4 months and the median progression-free survival (PFS) was 16.9 months. These results compare favorably with the historical standard of care results of 6.9 months PFS and 14.6 months OS, respectively. At a median follow-up time of 40 months, six of the newly diagnosed patients remained tumor free. Further analysis of the level of expression of the target proteins on patient tumor cells showed longer survival in patients with higher levels of some proteins and studies of tumor in patients who relapsed showed decreases in some of the target proteins, including a marker of cancer stem cells.

    These findings support the scientific rationale for using this therapeutic vaccine approach."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.094-0.0057(-5.72%)Oct 27 4:00 PMEDT